However, the TCR recognizes peptides from intracellular proteins presented on the surface of the tumor cell in the major histocompatibility complex (MHC) class I molecules, and loss or down-regulation of MHC molecules is a major source of tumor escape from immune surveillance which could limit the efficacy of TCR-based therapies [44]. This evidence concerns the gene HLA-C and neoplasm.